The three-week delay announcement came at 6:47 a.m. on a Tuesday, and Claire read it standing barefoot in her kitchen with a mug of coffee going cold in her hand.
Vanterra's board had "elected to extend the proxy timeline to allow for stakeholder consultation." Nine paragraphs of corporate throat-clearing, but the sentence that mattered was buried in the fourth one: *the parties have agreed to postpone the vote pending review of community and regulatory feedback.*
She read it twice. Then she called Ethan.
"I saw it," he said, before she could speak. "Marcus flagged it at five."
"Three more weeks."
"Maybe. Vanterra's general counsel isn't doing this out of the goodness of her heart. They're worried the patient testimony hurt them with institutional shareholders. This is a fig leaf."
"A fig leaf is still time." She set the mug down. "Ethan. We could actually fund it."
There was a pause, the particular silence of him thinking. She'd learned to read it over the last year—the way he went quiet when he was deciding whether to say the brave thing or the cautious one.
"Come to the office," he said. "I'll pull the old grant templates. I've got a list of foundations I've been meaning to burn."
They worked out of a borrowed conference room on the fourth floor, because Claire's office had become a staging ground for press and Ethan's had a window that faced the wrong direction and he claimed it depressed him. The room they took had a whiteboard and a broken blinds cord and a coffee machine that shrieked, which made it, in Claire's estimation, perfect.
The first week was a slaughter.
Eleven foundations. Nine rejections, most phrased in the soft language of institutional cowardice—*not a fit for our current funding priorities*—which Claire had learned to translate as *we don't want to be in the same sentence as a company that's suing people.*
"Pemberton said no," she reported on Thursday, dropping a printout on the table. "Their program officer told me off the record that their board chair sits on Vanterra's advisory council."
Ethan didn't look up from his laptop. "Then he's conflicted and he knows it. That's useful."
"It's not useful, it's obstruction."
"It's documented obstruction." He turned the screen toward her. "Which is exactly the kind of thing that makes the *next* foundation want to say yes. Nobody funds a fight that's already lost."
She stared at him. "You're enjoying this."
"I'm not." A pause. "I'm enjoying watching you not quit. That's different."
She felt the heat climb her throat and turned back to the whiteboard, where the running list of prospects had shrunk from eleven to two.
"Gates won't touch it," she said. "Too close to a live FDA matter. That leaves the Marchetti Fund and—" She stopped.
"And what?"
"Bramble Ridge. Small family foundation, Vermont. They fund patient-safety work. Their trustee is a woman named Constance Halloway, and her daughter died in 2014 from a pacemaker lead that was recalled six months after implant." Claire uncapped a marker. "That's not in their published materials. Deborah dug it out of a deposition."
Ethan was quiet for a moment. "You want to go to Vermont."
"I want to ask her to fund a study that makes sure nobody's daughter dies from a device that ignored her because she was a woman." Claire wrote the name on the board. "Yes. I want to go to Vermont."
They drove up on a Sunday, three hours north through a rain that turned to sleet somewhere past Concord and didn't let up until the Green Mountains closed around them. Ethan drove. Claire read the grant proposal aloud twice, then a third time, editing sentences with a pen in the margin until the pages looked like a wound.
"It's too long," she said.
"It's the right length."
"It's defensive. Look at this paragraph—" she flipped back. "*Given the historical underrepresentation of female subjects in cardiovascular device trials*, I sound like I'm apologizing for existing."
"You sound like you're citing the FDA's own guidance document."
"I sound like a lawyer wrote me."
"A lawyer did write you. You asked her to." He glanced over. "Read me the opening again."
She did. *The CardioSense gender-variable algorithm is the first cardiac decision-support system with sex-specific parameters validated in a prospective cohort. It is also, at present, the only one in the world. If the confirmatory trial is cancelled, that parameter set disappears from the approval—and the device reverts to the model that missed heart attacks in women at a rate of one in three.*
"Stop there," Ethan said. "That's the one."
Constance Halloway's house sat at the end of a gravel drive, a low stone building with a woodstove going and a dog that regarded them with suspicion from a bed by the fire. She was seventy-one, gray-haired and straight-backed, and she looked at Claire's business card for a long moment before she set it down.
"You're the one from the news," she said. "The whistleblower."
"I hate that word," Claire said.
"Good." Constance gestured at the couch. "Sit. Tell me why you're not just trying to save your own product."
It took an hour. Ethan said almost nothing, which Claire had learned to recognize as deliberate—he was there so Constance could see him, a cardiologist who'd left a hospital to do this, and the seeing was the argument. She asked hard questions. Why hadn't the FDA caught it. Why had the confirmatory sites been dropped. What would happen to the algorithm if Vanterra wound the company down.
"Nothing," Claire said. "It gets shelved. The label element survives on paper and disappears from the next generation of devices, because the company that owns the IP has no incentive to transfer it. That's the whole threat. Not that the trial fails—that the trial never happens and nobody notices."
Constance looked at the fire for a while.
"My daughter's name was Ellen," she said. "She was thirty-four. She had a lead that was supposed to be fine for ten years and it perforated in fourteen months. The company knew. The data was in their own registry. They told themselves it was noise." She looked back at Claire. "You're going to get sued."
"Almost certainly."
"And you'll be deposed, and they'll go through your emails, and someone will try to make you look like a disgruntled employee with an axe to grind."
"Yes."
Constance nodded slowly. "Good," she said. "Then you're serious."
The grant came through eleven days later, on a Friday afternoon, in a two-paragraph email that Claire read standing in the conference room doorway with her coat still on.
*$1.4 million over twenty-four months. Restricted to an independent prospective validation of the CardioSense sex-specific parameter set, conducted at an institution unaffiliated with Helix or Vanterra. Governance subject to a steering committee with patient representation.*
She read it again. The number didn't change.
"Ethan."
He was across the hall, in the doorway of his own borrowed office, and he looked up at her voice and something in his face shifted before she even said anything—like he'd heard it in the way she'd said his name.
"We got it."
He crossed the hall in three strides and read the email over her shoulder, and she felt him go very still, and then he laughed—a real one, startled out of him, the kind she almost never heard—and pulled her into a hug that lifted her off her feet for half a second before he set her down.
"Sorry," he said. "Sorry. That was—"
"That was fine." Her hands were still on his shoulders. Neither of them moved.
The office was empty, everyone else gone for the weekend. The blinds cord still broken, the coffee machine silent for once, and the rain from the drive to Vermont finally caught up with them, ticking against the window.
"Claire."
"I know," she said.
"I've been trying to say it in a way that doesn't sound like I'm taking advantage of a crisis."
"You're not."
"I'm your collaborator on a study that just got funded for a million four." His hands hadn't left her back. "There's a review board at the institute that will have opinions about this."
She laughed, and it came out shakier than she meant. "Let them."
He kissed her then, in the doorway of a borrowed office with the grant open on her phone, and it wasn't dramatic and it wasn't cinematic and it was better than either—a long, unhurried kiss that tasted like the coffee they'd both been drinking all day, with the rain working at the window and the hallway lights humming overhead.
When they broke apart he rested his forehead against hers.
"I should have done that a year ago," he said.
"You were grieving," she said. "You were allowed."
"That's not why."
"Then why?"
"Because I thought you'd leave." His voice was low. "Baltimore. I thought you'd go, and I thought if I said it you'd stay for the wrong reason, and I didn't want to be the wrong reason." He pulled back to look at her. "And then you stayed anyway."
"I stayed because it was the right thing."
"I know. That's the point." He tucked a strand of hair behind her ear, an oddly careful gesture for a man who did everything fast. "You didn't need me to give you a reason."
She stood there a moment, letting the whole weight of the last year settle somewhere behind her sternum.
"Sarah's drafting the IRB submission Monday," she said finally. "We need a data monitoring committee. Three clinicians, two patient reps, no Helix affiliations."
"Deborah's already got two names."
"Then we're starting." She pulled her coat off and hung it on the back of a chair, and Ethan watched her do it with an expression she was only just beginning to let herself read.
"Starting," he agreed.
They ordered takeout and worked until eleven, and the rain kept up the whole time, and somewhere around nine Claire looked up and realized she had stopped counting the reasons she was staying—which meant she'd run out of them, and all that was left was the staying itself.
That felt like enough. More than enough.